카테고리 없음

Dual-Action Therapy for Dyslipidemia: Combrog Tab

푸파시 2025. 6. 24. 11:23
728x90
반응형

① What is Combrog Tab?

Combrog Tab is a combination medication used to treat dyslipidemia.
It contains two active ingredients: Rosuvastatin Calcium and Ezetimibe.
Each works via a different mechanism to effectively lower LDL cholesterol levels.

Rosuvastatin inhibits cholesterol synthesis in the liver, while Ezetimibe blocks intestinal absorption of cholesterol.
This dual approach enables a stronger and faster LDL-C reduction than using either component alone.

② Active Ingredients and Mechanism of Action

  1. Rosuvastatin:
    As an HMG-CoA reductase inhibitor (statin), it reduces cholesterol synthesis in the liver and increases LDL receptor expression, promoting LDL clearance.
  2. Ezetimibe:
    It blocks NPC1L1, a protein responsible for cholesterol absorption in the intestines.
    This inhibits the uptake of both dietary and biliary cholesterol.

Together, these mechanisms provide enhanced lipid-lowering effects for patients requiring aggressive control.

③ Therapeutic Effects and Expected Benefits

  1. Significant LDL-C Reduction
    Compared to monotherapy, the combination offers an additional 15–25% LDL-C reduction, with possible reductions exceeding 50% in high-risk patients.
  2. Prevention of Cardiovascular Disease
    Lowering LDL-C helps reduce the risk of heart attack, stroke, and atherosclerosis.
    Combrog Tab is a key player in cardiovascular risk reduction.
  3. For Primary and Secondary Prevention
    Useful for patients not achieving targets with statins alone, and for those with a history of cardiovascular events (secondary prevention).

④ Side Effects and Precautions

  1. Muscle-Related Issues
    Rare cases of myalgia, myopathy, or rhabdomyolysis may occur.
    Symptoms like muscle weakness, dark urine, or fatigue warrant immediate medical attention.
  2. Liver Function Abnormalities
    Liver enzymes may rise, especially with long-term use. Routine liver function tests (AST, ALT) are recommended.
  3. Gastrointestinal Symptoms and Headache
    Some patients may experience mild abdominal discomfort, diarrhea, or headaches, which are usually transient.
  4. Not Recommended for Pregnant or Breastfeeding Women
    Due to potential harm to the fetus, women of childbearing age must use contraception during treatment.

⑤ Related Foods and Nutritional Considerations

  • For Rosuvastatin:
    Reduce saturated and trans fats. Increase intake of omega-3-rich fatty fish like salmon and mackerel to support heart health.
  • For Ezetimibe:
    • High-fiber foods (oats, barley, legumes) help bind and eliminate bile acids and cholesterol.
    • Plant sterol–rich foods (broccoli, sunflower seeds, almonds) help block cholesterol absorption in the gut.

Combining these dietary approaches with Combrog Tab enhances lipid control and long-term outcomes.

⑥ Summary

Combrog Tab is a fixed-dose combination of a statin (rosuvastatin) and ezetimibe, providing a strong, dual-action treatment for high LDL cholesterol.
It is especially effective for patients who fail to reach lipid targets with statins alone or those in high-risk categories.

Monitoring for muscle symptoms, liver function, and digestive issues is important.
With proper blood tests and dietary management, Combrog Tab offers optimal control of dyslipidemia.

728x90
반응형